Clinical trial
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
NCT04739800 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- June 10, 2021
- Completion date
- June 25, 2027
- Enrollment
- 120 (actual)
- Sites
- 391
Conditions
As the registry lists them; a condition with its own page is linked.
fallopian tube mucinous adenocarcinoma, ovarian seromucinous carcinoma, platinum-refractory fallopian tube carcinoma, platinum-refractory ovarian carcinoma, platinum-refractory primary peritoneal carcinoma, recurrent fallopian tube clear cell adenocarcinoma, recurrent fallopian tube endometrioid adenocarcinoma, recurrent fallopian tube high grade serous adenocarcinoma, recurrent fallopian tube mucinous adenocarcinoma, recurrent fallopian tube transitional cell carcinoma, recurrent fallopian tube undifferentiated carcinoma, recurrent low grade fallopian tube serous adenocarcinoma, recurrent ovarian clear cell adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian high grade serous adenocarcinoma, recurrent ovarian low grade serous adenocarcinoma, recurrent ovarian mucinous adenocarcinoma, recurrent ovarian seromucinous carcinoma, recurrent ovarian transitional cell carcinoma, recurrent ovarian undifferentiated carcinoma, recurrent platinum-resistant fallopian tube carcinoma, recurrent platinum-resistant ovarian carcinoma, recurrent platinum-resistant primary peritoneal carcinoma, recurrent primary peritoneal clear cell adenocarcinoma, recurrent primary peritoneal endometrioid adenocarcinoma, recurrent primary peritoneal high grade serous adenocarcinoma, recurrent primary peritoneal low grade serous adenocarcinoma, recurrent primary peritoneal transitional cell carcinoma, recurrent primary peritoneal undifferentiated carcinoma, refractory fallopian tube clear cell adenocarcinoma, refractory fallopian tube endometrioid adenocarcinoma, refractory fallopian tube high grade serous adenocarcinoma, refractory fallopian tube mucinous adenocarcinoma, refractory fallopian tube transitional cell carcinoma, refractory fallopian tube undifferentiated carcinoma, refractory low grade fallopian tube serous adenocarcinoma, refractory ovarian clear cell adenocarcinoma, refractory ovarian endometrioid adenocarcinoma, refractory ovarian high grade serous adenocarcinoma, refractory ovarian low grade serous adenocarcinoma, refractory ovarian mucinous adenocarcinoma, refractory ovarian seromucinous carcinoma, refractory ovarian transitional cell carcinoma, refractory ovarian undifferentiated carcinoma, refractory primary peritoneal clear cell adenocarcinoma, refractory primary peritoneal endometrioid adenocarcinoma, refractory primary peritoneal high grade serous adenocarcinoma, refractory primary peritoneal low grade serous adenocarcinoma, refractory primary peritoneal transitional cell carcinoma, refractory primary peritoneal undifferentiated carcinoma